Search research articles
Contact Us
Filters
Showing results (211-220 of 252) with videos related to
Page
of 26
Sort By:
Frontiers in Immunology
|
November 21, 2022
Relationships of circulating CD4<sup>+</sup> T cell subsets and cytokines with the risk of relapse in patients with Crohn's disease
Rémi Duclaux-Loras, Gilles Boschetti, Bernard Flourie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents
Pauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
The American Journal of Gastroenterology
|
August 16, 2022
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID
Gilles Boschetti, Maria Nachury, David Laharie, et al.
The Lancet. Gastroenterology & Hepatology
|
December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial
Séverine Vermeire, Stefan Schreiber, David T Rubin, et al.
Journal of Crohn'S & Colitis
|
January 14, 2020
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study
Antoine Martin, Maria Nachury, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics
|
April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study
Aurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
The Lancet. Gastroenterology & Hepatology
|
November 21, 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
Geert D'Haens, Carlos Taxonera, Antonio Lopez-Sanroman, et al.
Alimentary Pharmacology & Therapeutics
|
July 23, 2021
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study
Mathurin Fumery, Jérôme Filippi, Vered Abitbol, et al.
Digestive Diseases and Sciences
|
March 5, 2022
Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study
Lucas Guillo, Aurélien Amiot, Mélanie Serrero, et al.
Journal of Crohn'S & Colitis
|
April 10, 2021
Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms
Bella Ungar, Karin Malickova, Jurij Hanžel, et al.
Page
of 26
Search research articles
Search
Showing results (211-220 of 252) with videos related to
Sort By:
Page
of 26
Frontiers in Immunology
|
November 21, 2022
Relationships of circulating CD4<sup>+</sup> T cell subsets and cytokines with the risk of relapse in patients with Crohn's disease
Rémi Duclaux-Loras, Gilles Boschetti, Bernard Flourie, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 4, 2015
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents
Pauline Wils, Yoram Bouhnik, Pierre Michetti, et al.
The American Journal of Gastroenterology
|
August 16, 2022
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID
Gilles Boschetti, Maria Nachury, David Laharie, et al.
The Lancet. Gastroenterology & Hepatology
|
December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial
Séverine Vermeire, Stefan Schreiber, David T Rubin, et al.
Journal of Crohn'S & Colitis
|
January 14, 2020
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study
Antoine Martin, Maria Nachury, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics
|
April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study
Aurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
The Lancet. Gastroenterology & Hepatology
|
November 21, 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
Geert D'Haens, Carlos Taxonera, Antonio Lopez-Sanroman, et al.
Alimentary Pharmacology & Therapeutics
|
July 23, 2021
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study
Mathurin Fumery, Jérôme Filippi, Vered Abitbol, et al.
Digestive Diseases and Sciences
|
March 5, 2022
Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study
Lucas Guillo, Aurélien Amiot, Mélanie Serrero, et al.
Journal of Crohn'S & Colitis
|
April 10, 2021
Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms
Bella Ungar, Karin Malickova, Jurij Hanžel, et al.
Page
of 26